<p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）的股价在周二市场开盘前跳涨。该股此前收于 216.56 美元，但开盘时为 221.89 美元。Ascendis Pharma A/S 的股票最后交易价格为 215.0240 美元，成交量为 36,841 股。</p>
<p>获取 <strong>Ascendis Pharma A/S</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>BioMarin 股票能否满足华尔街的高期望？</li>
</ul>
<p>几位股票分析师最近对 ASND 股票发表了评论。美国银行在 9 月 2 日的研究报告中将 Ascendis Pharma A/S 的目标价从 227.00 美元上调至 230.00 美元，并给予该公司 “买入” 评级。摩根大通在 10 月 9 日的研究报告中将 Ascendis Pharma A/S 的目标价从 260.00 美元上调至 264.00 美元，并给予该公司 “增持” 评级。富国银行在 8 月 8 日的报告中重申了 “增持” 评级，并将 Ascendis Pharma A/S 的目标价上调至 295.00 美元（之前为 289.00 美元）。Weiss Ratings 在 10 月 8 日的报告中重申了对 Ascendis Pharma A/S 股票的 “卖出（d-）” 评级。最后，Cowen 在 8 月 8 日的研究报告中重申了对 Ascendis Pharma A/S 股票的 “买入” 评级。一位研究分析师给予该股 “强烈买入” 评级，十四位分析师给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “适度买入”，共识目标价为 256.60 美元。</p>
<p><strong>查看我们关于 Ascendis Pharma A/S 的最新研究报告</strong></p>
<h2>Ascendis Pharma A/S 股票上涨 1.8%</h2>
<ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
<p>该公司的市值为 136 亿美元，市盈率为-42.80，贝塔值为 0.44。该公司的 50 日移动平均线为 202.09 美元，200 日移动平均线为 185.16 美元。</p>
<p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）最近在 11 月 12 日发布了季度财报。这家生物技术公司报告每股收益（EPS）为-1.17 美元，低于市场共识预期的-0.41 美元，差距为-0.76 美元。该公司在本季度的收入为 2.9024 亿美元，而分析师预期为 2.4691 亿美元。平均而言，研究分析师预计 Ascendis Pharma A/S 在当前年度的每股收益为-4.34 美元。</p>
<h2>对 Ascendis Pharma A/S 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近对 ASND 的持仓进行了调整。Perceptive Advisors LLC 在第二季度购买了 Ascendis Pharma A/S 的新股份，价值约为 1.66367 亿美元。Wellington Management Group LLP 在第三季度将其在 Ascendis Pharma A/S 的持仓增加了 95.9%。Wellington Management Group LLP 目前拥有 1,798,931 股该生物技术公司的股票，价值为 3.57645 亿美元，此前在上个季度增持了 880,836 股。Principal Financial Group Inc.在第三季度将其在 Ascendis Pharma A/S 的持仓增加了 2,722.9%。Principal Financial Group Inc.目前拥有 793,677 股该生物技术公司的股票，价值为 1.57791 亿美元，此前在上个季度增持了 765,561 股。Vestal Point Capital LP 在第三季度将其在 Ascendis Pharma A/S 的持仓增加了 200.0%。Vestal Point Capital LP 目前拥有 600,000 股该生物技术公司的股票，价值为 1.19286 亿美元，此前在此期间增持了 400,000 股。最后，Spyglass Capital Management LLC 在第三季度购买了 Ascendis Pharma A/S 的新股份，价值约为 7726.7 万美元。</p>
<h2>Ascendis Pharma A/S 公司简介</h2>
<p>（获取免费报告）</p>
<p>Ascendis Pharma A/S 是一家生物制药公司，专注于开发满足未满足医疗需求的疗法。它提供 SKYTROFA 用于治疗生长激素缺乏症（GHD）患者。该公司还在临床开发中开发三种独立的内分泌罕见疾病产品候选药物，并专注于推进肿瘤治疗候选药物。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Ascendis Pharma A/S</li>
<li>上海证券交易所综合指数是什么？</li>
<li>为什么 20 秒的飞行测试可能为垂直市场解锁数十亿美元</li>
<li>如何投资小盘股</li>
<li>3 只适合不安市场的聪明防御性股票</li>
<li>股票交易：RSI 及其用途</li>
<li>这 3 只股票正在利用回购来传达市场信心</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ascendis Pharma A/S 吗？</h2>
<p>在考虑 Ascendis Pharma A/S 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ascendis Pharma A/S 并不在名单上。</p>
<p>虽然 Ascendis Pharma A/S 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Ascendis制药

<p>Ascendis Pharma A/S（纳斯达克代码：ASND）股票开盘价为 221.89 美元，较前一交易日的 216.56 美元上涨，但最后交易价为 215.0240 美元。分析师们设定了新的目标价，摩根大通、美国银行和富国银行均给予 “买入” 或 “增持” 评级。该股票的共识评级为 “适度买入”，目标价为 256.60 美元。公司报告的季度每股收益为（1.17 美元），未能达到预期，市值为 136 亿美元</p>

<p>Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $216.56, but opened at $221.89. Ascendis Pharma A/S shares last traded at $215.0240, with a volume of 36,841 shares changing hands.</p>
<div class="lb-trans"><p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）的股价在周二市场开盘前跳涨。该股此前收于 216.56 美元，但开盘时为 221.89 美元。Ascendis Pharma A/S 的股票最后交易价格为 215.0240 美元，成交量为 36,841 股。</p>
</div><p>Get <strong>Ascendis Pharma A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ascendis Pharma A/S</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>BioMarin 股票能否满足华尔街的高期望？</li>
</ul>
</div><p>Several equities analysts have recently commented on ASND shares. Bank of America boosted their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, September 2nd. JPMorgan Chase &amp; Co. lifted their target price on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 9th. Wells Fargo &amp; Company reissued an &#34;overweight&#34; rating and issued a $295.00 price target (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Finally, Cowen reiterated a &#34;buy&#34; rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $256.60.</p>
<div class="lb-trans"><p>几位股票分析师最近对 ASND 股票发表了评论。美国银行在 9 月 2 日的研究报告中将 Ascendis Pharma A/S 的目标价从 227.00 美元上调至 230.00 美元，并给予该公司 “买入” 评级。摩根大通在 10 月 9 日的研究报告中将 Ascendis Pharma A/S 的目标价从 260.00 美元上调至 264.00 美元，并给予该公司 “增持” 评级。富国银行在 8 月 8 日的报告中重申了 “增持” 评级，并将 Ascendis Pharma A/S 的目标价上调至 295.00 美元（之前为 289.00 美元）。Weiss Ratings 在 10 月 8 日的报告中重申了对 Ascendis Pharma A/S 股票的 “卖出（d-）” 评级。最后，Cowen 在 8 月 8 日的研究报告中重申了对 Ascendis Pharma A/S 股票的 “买入” 评级。一位研究分析师给予该股 “强烈买入” 评级，十四位分析师给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “适度买入”，共识目标价为 256.60 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Ascendis Pharma A/S</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Ascendis Pharma A/S 的最新研究报告</strong></p>
</div><h2>Ascendis Pharma A/S Stock Up 1.8%</h2>
<div class="lb-trans"><h2>Ascendis Pharma A/S 股票上涨 1.8%</h2>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
</div><p>The company has a market capitalization of $13.60 billion, a P/E ratio of -42.80 and a beta of 0.44. The business has a 50 day moving average of $202.09 and a 200 day moving average of $185.16.</p>
<div class="lb-trans"><p>该公司的市值为 136 亿美元，市盈率为-42.80，贝塔值为 0.44。该公司的 50 日移动平均线为 202.09 美元，200 日移动平均线为 185.16 美元。</p>
</div><p>Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $290.24 million during the quarter, compared to analyst estimates of $246.91 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.</p>
<div class="lb-trans"><p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）最近在 11 月 12 日发布了季度财报。这家生物技术公司报告每股收益（EPS）为-1.17 美元，低于市场共识预期的-0.41 美元，差距为-0.76 美元。该公司在本季度的收入为 2.9024 亿美元，而分析师预期为 2.4691 亿美元。平均而言，研究分析师预计 Ascendis Pharma A/S 在当前年度的每股收益为-4.34 美元。</p>
</div><h2>Hedge Funds Weigh In On Ascendis Pharma A/S</h2>
<div class="lb-trans"><h2>对 Ascendis Pharma A/S 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in ASND. Perceptive Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $166,367,000. Wellington Management Group LLP grew its position in Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company's stock worth $357,645,000 after acquiring an additional 880,836 shares in the last quarter. Principal Financial Group Inc. increased its stake in Ascendis Pharma A/S by 2,722.9% during the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company's stock worth $157,791,000 after acquiring an additional 765,561 shares during the last quarter. Vestal Point Capital LP raised its position in Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company's stock valued at $119,286,000 after purchasing an additional 400,000 shares during the period. Finally, Spyglass Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $77,267,000.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对 ASND 的持仓进行了调整。Perceptive Advisors LLC 在第二季度购买了 Ascendis Pharma A/S 的新股份，价值约为 1.66367 亿美元。Wellington Management Group LLP 在第三季度将其在 Ascendis Pharma A/S 的持仓增加了 95.9%。Wellington Management Group LLP 目前拥有 1,798,931 股该生物技术公司的股票，价值为 3.57645 亿美元，此前在上个季度增持了 880,836 股。Principal Financial Group Inc.在第三季度将其在 Ascendis Pharma A/S 的持仓增加了 2,722.9%。Principal Financial Group Inc.目前拥有 793,677 股该生物技术公司的股票，价值为 1.57791 亿美元，此前在上个季度增持了 765,561 股。Vestal Point Capital LP 在第三季度将其在 Ascendis Pharma A/S 的持仓增加了 200.0%。Vestal Point Capital LP 目前拥有 600,000 股该生物技术公司的股票，价值为 1.19286 亿美元，此前在此期间增持了 400,000 股。最后，Spyglass Capital Management LLC 在第三季度购买了 Ascendis Pharma A/S 的新股份，价值约为 7726.7 万美元。</p>
</div><h2>Ascendis Pharma A/S Company Profile</h2>
<div class="lb-trans"><h2>Ascendis Pharma A/S 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.</p>
<div class="lb-trans"><p>Ascendis Pharma A/S 是一家生物制药公司，专注于开发满足未满足医疗需求的疗法。它提供 SKYTROFA 用于治疗生长激素缺乏症（GHD）患者。该公司还在临床开发中开发三种独立的内分泌罕见疾病产品候选药物，并专注于推进肿瘤治疗候选药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Ascendis Pharma A/S</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Why a 20-Second Flight Test Could Unlock Billions for Vertical</li>
<li>How to Invest in Small Cap Stocks</li>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Ascendis Pharma A/S</li>
<li>上海证券交易所综合指数是什么？</li>
<li>为什么 20 秒的飞行测试可能为垂直市场解锁数十亿美元</li>
<li>如何投资小盘股</li>
<li>3 只适合不安市场的聪明防御性股票</li>
<li>股票交易：RSI 及其用途</li>
<li>这 3 只股票正在利用回购来传达市场信心</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ascendis Pharma A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ascendis Pharma A/S 吗？</h2>
</div><p>Before you consider Ascendis Pharma A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ascendis Pharma A/S 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ascendis Pharma A/S 并不在名单上。</p>
</div><p>While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ascendis Pharma A/S 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ascendis Pharma A/S (NASDAQ:ASND) 股价跳空上涨 - 接下来会如何发展？